To investigate whether this was a coincidence or may be applicable more broadly, we extended our study to an established panel of NSCLC cell lines.38 This panel includes cells that are mutated in KRAS and/or p53 (Supplementary Figure S6a). The gene discussed is TP53; the disease is non-small cell lung carcinoma.